drugset
drugset / Trial / NCT04670770

An Open Label Study of the Effects of SHR1459 in NMOSDs Patients

NCT04670770 ↗

Phase 2 Completed 10 enrolled Reistone Biopharma Company Limited
NaSingle-groupOpen-labelTreatment

Summary

This is an open-label study, to evaluate the efficacy and safety of SHR1459 in participants with NMOSDs.

Timeline

Start
2021-01-20
Primary completion
2022-08-15
Completion
2022-08-15

Drugs

EvaluationDrugModalityDoseRoute
Subject EDRALBRUTINIB Small molecule — Oral

Indications

neuromyelitis optica